About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Systemic Diseases group performs translational research based on at least 300 patients with systemic lupus erytomatosus (SLE), antiphospholipid syndrome (APS), systemic sclerosis, vasculitis, dermatomyitis, Sjörgen syndrome or autoinflammatory syndromes in order to better understand their pathogenesis (both at the immunological and genetic regulation level), study their clinical and biological expression (through the detection of new markers that help characterize each of the autoimmune diseases), study morbimortality (through epidemiological studies) and analyse patients' response to medications. With these goals in mind, we seek to improve the diagnosis, clinical monitoring, and prognosis of our patients.
PMID: 34075090 Journal: Scientific Reports Year: 2021 Reference: Sci Rep. 2021 Jun 1;11(1):11462. doi: 10.1038/s41598-021-90797-0. Impact factor: 4.38 Publication type: Paper in international publication Authors: Julia, Antonio, Bonafonte-Pardas, Irene, Gomez, Antonio, Lopez-Lasanta, Maria, Lopez-Corbeto, Mireia, Martinez-Mateu, Sergio H, Llados, Jordi, Rodriguez-Nunez, Ivan, Myers, Richard M, Marsal, Sara et al. DOI: 10.1038/s41598-021-90797-0
PMID: 34025983 Journal: Clinical and Translational Allergy Year: 2021 Reference: Clin Transl Allergy. 2021 May 18;11(3):e12010. doi: 10.1002/clt2.12010. eCollection 2021 May. Impact factor: 5.871 Publication type: Review in international publication Authors: Faber, Margaretha A, Skypala, Isabel J, Asero, Ricardo, Barber, Domingo, Cecchi, Lorenzo, Diaz Perales, Arazeli, Hoffmann-Sommergruber, Karin, Pastorello, Elide A, Swoboda, Ines, Bartra, Joan et al. DOI: 10.1002/clt2.12010
PMID: 33996816 Journal: Frontiers in Cell and Developmental Biology Year: 2021 Reference: Front Cell Dev Biol. 2021 Apr 29;9:655201. doi: 10.3389/fcell.2021.655201. eCollection 2021. Impact factor: 6.684 Publication type: Paper in international publication Authors: Garcia-Montolio, Marc, Ballare, Cecilia, Blanco, Enrique, Gutierrez, Arantxa, Aranda, Sergi, Gomez, Antonio, Kok, Chung H, Yeung, David T, Hughes, Timothy P, Vizan, Pedro et al. DOI: 10.3389/fcell.2021.655201
PMID: 33999255 Journal: SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES Year: 2021 Reference: Surg Endosc. 2021 Jul;35(7):3233-3243. doi: 10.1007/s00464-021-08524-9. Epub 2021 May 17. Impact factor: 4.584 Publication type: Paper in international publication Authors: Antoniou, Stavros A, Mavridis, Dimitris, Kontouli, Katerina Maria, Drakopoulos, Vasileios, Gorter-Stam, Marguerite, Eriksson, Sture, Leone, Marc, Perez-Bocanegra, Maria Carmen, Smart, Neil J, Milone, Marco et al. DOI: 10.1007/s00464-021-08524-9
PMID: 30767873 Journal: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY Year: 2019 Reference: Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):41-48. Epub 2019 Feb 11. Impact factor: 3.238 Publication type: Paper in international publication Authors: Callejas-Moraga, Eduardo Luis, Guillen-Del-Castillo, Alfredo, Marin-Sanchez, Ana Maria, Roca-Herrera, Maria, Balada, Eva, Tolosa-Vilella, Carles, Fonollosa-Pla, Vicente, Simeon-Aznar, Carmen Pilar et al. DOI:
PMID: 30552173 Journal: ANNALS OF THE RHEUMATIC DISEASES Year: 2019 Reference: Ann Rheum Dis. 2019 Mar;78(3). pii: annrheumdis-2018-214158. doi: 10.1136/annrheumdis-2018-214158. Epub 2018 Dec 14. Impact factor: 14.299 Publication type: Paper in international publication Authors: Alperi-Lopez, Mercedes, Blanco, Ricardo, Willisch Dominguez, Alfredo, Mosquera, Jose Antonio, Vela, Paloma, Sanchez-Fernandez, Simon Angel, Corominas, Hector, Ramirez, Julio, de la Cueva, Pablo, Fonseca, Eduardo et al. DOI: 10.1136/annrheumdis-2018-214158
PMID: 30763732 Journal: Journal of Allergy and Clinical Immunology-In Practice Year: 2019 Reference: J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):2057-2058. doi: 10.1016/j.jaip.2019.01.052. Epub 2019 Feb 11. Impact factor: 7.55 Publication type: Paper in international publication Authors: Gil-Serrano, Johana, Cardona, Victoria, Luengo, Olga, Guilarte, Mar, Labrador-Horrillo, Moises, Galvan-Blasco, Paula, Sala-Cunill, Anna et al. DOI: 10.1016/j.jaip.2019.01.052
PMID: 30760090 Journal: LUPUS Year: 2019 Reference: Lupus. 2019 Mar;28(3):396-405. doi: 10.1177/0961203319828521. Epub 2019 Feb 13. Impact factor: 2.924 Publication type: Paper in international publication Authors: Garcia-Vives, E, Sole, C, Moline, T, Alvarez-Rios, A M, Vidal, M, Agraz, I, Ordi-Ros, J, Cortes-Hernandez, J et al. DOI: 10.1177/0961203319828521
The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.
Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.
It will allow the promotion of research on systemic autoimmune-based diseases that especially affect women of childbearing age and, therefore, can also appear during pregnancy.
